rais fve optimist profit
project still moat
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
despit well-establish track record introduc
precis sensor use continu glucos monitor
firm main focu enhanc accuraci cgm
perform may enough fend competit
strength technolog captur impress
slice cgm market howev contend sever
factor histor hinder abil expand cgm
market view bigger opportun moreov
tougher competit abbott could hurt
use larg center among type diabet
penetr estim around partli
relat greater need patient pool versu type
keep closer tab blood glucos read similarli payer
reluct expand reimburs beyond type
popul meant face uphil battl
expand type market
abbott introduc meaning innov
realm think could sway patient away
abbott freestyl libr flash significantli user-friendli
aggress price expect product make
substanti inroad type popul medtron new
insulin pump autom much insulin deliveri
come integr cgm new competit
featur could outweigh improv accuraci stick-fre featur
sensor life new next-gen product
factor work favor first
precis cgm remain materi better competit
firm establish medicar
reimburs cgm basi accuraci
incorpor latest featur
includ factor calibr final allianc
tandem verili googl healthcar incub provid
opportun firm potenti gener disrupt
technolog
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
design commerci continu glucos monitor cgm
system diabet cgm system serv altern tradit
glucomet process compani sell three differ piec
equip sensor transmitt receiv
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
substanti boost fair valu estim
per share incorpor optimist
project profit arriv sooner
follow next-gen gain ground
yet reach profit firm continu invest
build manufactur footprint sale
infrastructur scale develop next five year
expect post meaning profit
overal forecast revenu compound-annual-growth-rate
roughli half histor norm reflect
competit abbott
diversifi rival run delay approv
manufactur constraint abbott
gotten past issu think appeal
minim integr guardian
connect cgm abbott freestyl libr devic lower
price point medicar reimburs offer
potenti user perhap first time sever
compel altern choos
larger revenu base
expect reach gross margin
oper margin expect
launch two gener no-calibr
devic creat verili furthermor
facil launch arizona weigh oper
near term expect support recent
medicar approv remov key barrier kept
older patient away
consid relianc singl product
current inabl earn profit tougher competit
abbott give high
bullish scenario assum intern creat
headwind continu stymi abbott
initi fail gain substanti foothold
space leav opportun solidifi
posit newer product like devic verili
product expand market opportun factori
calibr longer sensor life attract user
previous entic cgm devic given
dynam forecast type diabet patient
type popul transit devic
fast rate furthermor begin valid
type non-intens market particularli
newer verily-partn product allow
compani appeal rapidli grow type market
scenario project revenu compound annual
growth rate next year bull-cas
fair valu estim per share
bear-cas scenario abbott chip away
domin market posit faster expect
anticip abbott strength freestyl libr
type space hurt
target user desir integr cgm nearli
closed-loop insulin pump combin scenario
model revenu compound annual growth rate
next year bear-cas fair valu estim
point think dug moat
similar firm earli stage fast growth
sub-scal oper yet reach profit
expect turn corner cross
black could easili delay thank
moat diagnost stem either switch cost
cost structur yet creat competit
advantag either area sever reason first
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
competit price aid new entrant carv slice
market situat face
claim alreadi hold lion share cgm
market addit dexcom
wide
acknowledg technolog leader even
competitor accur sensor
consist roll improv cgm technolog
sixth-gener product
technolog innov associ market share
leadership usual characterist moati firm
wield price power case weve seen littl
evid translat technolog
superior long-term price power exampl
dexcom sensor last seven day price
per day asp manag alreadi
indic would hold steadi asp
sensor even though new product last day
could potenti lower revenu
higher-margin consum depend mani
current patient use sensor indic
think face neg moat trend
first long-held ambit penetr sizabl
segment type market need multipl daili
insulin inject could benefit cgm use thu far
payer gener reluct establish
reimburs among group patient
kept limit smaller type market
freestyl libr flash offer similar
featur includ factori calibr fda
approv dose decis howev libr flash
price significantli lower
third also face disadvantag type
market mani cgm user also use
switch cost second diagnost dexcom
face difficulti link diagnost healthcar
outcom closer linkag outcom stronger
manufactur negoti payer
recogn made progress front
recent therapeut indic mean patient
make treatment decis base read without
confirm blood glucos level tradit meter
howev simpli go far enough opinion
key rival offer competit cgm
integr insulin pumpth actual therapeut
deviceand instruct pump much
insulin releas remain far closer
therapi happen cgm enabl
therapi
final suspect manag made deliber
decis focu gain market share expens
profit weve seen sort competit
price strategi usual employ smaller
competitor seek enter market
well-establish competitor alreadi domin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
insulin pump allianc
product integr tandem anima pump
offer pump hold
estim share insulin pump market
tandem anima hold less
addit johnson johnson exit pump
busi discontinu manufactur anima product
encourag patient transit medtron
integr pump cgm system
think meaning hybrid closed-loop innov
attract competit pump user well
convert type pump multipl daili
inject anticip patient opt
medtron guardian cgm integr
pump instead keep two separ devic
monitor pump
final asid tradit rival dexcom
may also need protect flank upstart
senseon produc eversens implant
sensor cgm system approv fda
summer eversens sensor implant upper
arm worn day elimin need
switch insert new sensor everi day
eversens transmitt secur worn
arm sensor data transmit via
smartphon app initi
indic may issu replac
eversens sensor expect new long-wear
cgm could attract type diabet offer
less complex non-diabet normalci
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
verili expect less expens offer
thinner profil longer sensor wear time
omedicar decis reimburs
favor develop privat
payer often use medicar benchmark
owhil littl detail initi
verili think great potenti appli tech
expertis data analyt data-intens health
manag diabet partnership could put
step ahead rival
ojohnson johnson decis exit pump
busi direct anima user medtron
ountil privat payer decid expand
reimburs includ type diabet dexcom
larg limit type market
must face behemoth
omor attract price abbott
could substanti cut adopt rate
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
cash flow posit four consecut
year yet post posit earn expect
move black next two year
revenu grown quickli research
develop expens sell gener
administr cost grown significantli well
fund oper loss addit capit
rais year convert debt
took substanti debt rel
histor level issu million
convert senior note matur dexcom
intent financ signific expans particularli
buildout compani manufactur facil arizona
note initi convers rate share
common stock per princip amount note
equat per share common
stock recent firm issu convert debt
partial redeem convert debt come due
note initi convers rate
equival per share also issu
million share rais fund pay hefti
consid relianc singl product
current inabl earn profit tougher competit
abbott give high
uncertainti rate dexcom greatest materi risk
better-than-expect adopt competit product
opinion alreadi expect strong adopt
abbott freestyl libr flash
guardian cgm market recept exce
optimist expect would bear brunt
addit pure play cgm opportun
financi well-being sole base growth one
type product unlik main competitor wide
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
diversifi progress abbott might make
expand reimburs could also hurt
share longer term doubt
whether technolog leadership enough
allow commerci success continu believ
type type intens diabet continu
seek product improv well-b make
solid underli demand howev think may
cede market share abbott
product improv accuraci offer addit featur
asid competit risk
also face gener medic devic risk
includ run afoul fda potenti product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
board director
board director
repres date owner name posit common share held report holder issuer
global internet thing etf
fidel manag research compani
share
fund
share
fund
gregg serv ceo eventu step
serv execut chairman role
maintain today former kevin sayer becam ceo
interest gregg sayer previous
serv role minim diabet manag system
acquir billion
believ experi may give manag team
addit insight diabet market
think manag long-term focu innov
sound like reach
creat strateg partnership busi
alphabet life scienc divis verili priorit
watch applaud manag invest creat
digit ecosystem around cgm data particularli
cgm info fed io android devic manag
diabet extrem data intens well suit
app would equip patient act cgm
read time manner also like
partner integr cgm energet pump
maker tandem though may
due necess anyth els
littl critic firm capit alloc
perspect remain earli stage
commerci high growth technolog
adopt manag continu invest next
improv strateg
allianc time posit
face decis alloc excess cash
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
dexcom wrap strength chang
finish year slightli stronger growth
sensor transmitt wed project
firm progress toward profit consist
expect leav fair valu estim
unchang manag outlook billion
billion revenu year struck us conserv
think like exceed rang
project revenu billion volum
offset lower price nonetheless still dont think
firm dug econom moat competit
continu strengthen suspect recent uptick
cgm insulin pump innov pull
patient away tradit glucos meter multipl
daili insulin inject lead increas penetr
newer technolog allow
abbott realiz strong perform
diabet franchis believ may point
penetr technolog may top
current pipelin meaning innov contain
dexcom closed-loop pump
like support greater penetr pump
explicit five-year forecast period
next year compar compound-annual-growth-rate weve
project seem unreason us impli
entir cgm market shi billion
need grow approxim eightfold billion
virtual market share
contrast estim impli captur
nearli share global cgm market size
billion consid impress innov
come abbott well what
pipelin improv close accuraci gap
think unlik abl
complet block competitor gain cgm share
rule unconstitut district court
near-term impact fundament dec
dec judg reed connor northern district
texa issu rule effect declar patient
protect afford act
unconstitut assum littl chang
compani cover healthcar sector
near term rule like make way
appeal process surpris see
case third appear make front
 suprem court potenti timelin final
asid greater competit also keep eye
declin revenu per patient gain strength
second half thank addit medicar
reimburs faster growth intern market
emerg access pharmaci channel
expect inroad retail pharmaci
near term could pressur revenu per patient
longer run anticip greater
access help race captur
patient
basi decis find root congress
elimin shared-respons financi penalti
accompani passag tax cut job act
late last year short judg connor found individu
mandat essenti insever provis
congress decis elimin enforc
tax penalti law render entireti
legisl unconstitut logic follow
 suprem court decis upheld
constitut congress power taxat
share remain overvalu perspect compound
annual top-lin growth would need averag
view healthcar provid sector at-risk
stem chang prevail healthcar
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
new technolog think put competit
pressur
face near-term headwind form
reduc revenu per patient mix custom
shift expect factor eas time
next year could get wors get better
particular intern sale medicar sale --
result lower revenu per patient -- like continu
grow larger proport total sale base
addit firm strategi expand access
pharmaci channel also mean like need
conced price negoti payer
manag confid greater volum realiz
pharmaci off-set price
concess anticip new channel help
captur type diabet core patient
segment skeptic firm potenti
among type ii thank abbott freestyl libr
substanti lower price long avail
applaud firm effort collabor virtual
entiti also involv therapi diabet
includ tandem novo nordisk
opportun innov market
algorithm diabet manag app patient
smartphon think allianc give
best chanc associ whatev new solut
wide adopt
legisl whether chang individu coverag
roll-back medicaid expans higher uninsur
rate unequivoc equat pressur hospit margin
payer perspect trade-off littl less clear
although medicaid-focus insur like feel
bulk enrol loss
intend make chang moat rate fair
valu estim result decis continu
monitor case make way appel
court come month outcom timelin
uncertain make meaning chang
assumpt earli day addit wildcard
potenti legisl action muddi
ultim financi penalti carri
insur coverag set end jan
understand feder govern intend
maintain statu quo appeal process
insur alreadi lock rate propos
earliest like see potenti effect
rule premium polici offer slate
open enrol season
dexcom see strong adopt hit headwind
price due payer channel mix
post strong third-quart result
gener consist expect
stand pat fair valu estim per share
roll continu fuel double-digit revenu
growth constant currenc year year
firm also saw good news medicar decis cover
therapeut devic patient need intens
insulin manag also look forward see
turn meaning profit next year nonetheless
remain reluct point award
narrow moat main continu glucos monitor
competitor also see success commerci
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
